Nutritional therapies in congenital disorders of glycosylation (CDG)

Nutrients

Volumn 9, Issue 11, 2017, Pages

  Witters, Peter ^a,b   Cassiman, David ^a   Morava, Eva ^a,b,c  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Congenital disorders of glycosylation (CDG); Diet; Galactose; Glycosylation; Mannose; Treatment

Indexed keywords

CREATINE KINASE; GALACTOSE; MANGANESE; MANNOSE; PHOSPHOGLUCOMUTASE;

CONGENITAL DISORDER OF GLYCOSYLATION; DIET THERAPY; HUMAN; HYPSARRHYTHMIA; NONHUMAN; REVIEW;

CONGENITAL DISORDERS OF GLYCOSYLATION; HUMANS; NUTRITION THERAPY;

EID: 85033464792     PISSN: None     EISSN: 20726643     Source Type: Journal    
DOI: 10.3390/nu9111222     Document Type: Review

References (41)

1. Jaeken, J.; Peanne, R. What is new in CDG? J. Inherit. Metab. Dis. 2017, 40, 569-586. [CrossRef] [PubMed]
2. Marques-da-Silva, D.; Dos Reis Ferreira, V.; Monticelli, M.; Janeiro, P.; Videira, P.A.; Witters, P.; Jaeken, J.; Cassiman, D. Liver involvement in congenital disorders of glycosylation (CDG). A systematic review of the literature. J. Inherit. Metab. Dis. 2017, 40, 195-207. [CrossRef] [PubMed]
3. Witters, P.; Morava, E. Congenital disorders of glycosylation (CDG): Review. eLS 2016, 1-6. [CrossRef]
4. Jaeken, J.; Hennet, T.; Matthijs, G.; Freeze, H.H. CDG nomenclature: Time for a change! Biochim. Biophys. Acta 2009, 1792, 825-826. [CrossRef] [PubMed]
5. Morelle, W.; Potelle, S.; Witters, P.; Wong, S.; Climer, L.; Lupashin, V.; Matthijs, G.; Gadomski, T.; Jaeken, J.; Cassiman, D. et al. Galactose supplementation in patients with tmem165-CDG rescues the glycosylation defects. J. Clin. Endocrinol. Metab. 2017, 102, 1375-1386. [CrossRef] [PubMed]
6. Lefeber, D.J.; Morava, E.; Jaeken, J. How to find and diagnose a CDG due to defective N-glycosylation. J. Inherit. Metab. Dis. 2011, 34, 849-852. [CrossRef] [PubMed]
7. Freeze, H.H. Congenital disorders of glycosylation: CDG-I, CDG-II, and beyond. Curr. Mol. Med. 2007, 7, 389-396. [CrossRef] [PubMed]
8. Barone, R.; Aiello, C.; Race, V.; Morava, E.; Foulquier, F.; Riemersma, M.; Passarelli, C.; Concolino, D.; Carella, M.; Santorelli, F. et al. DPM2-CDG: A muscular dystrophy-dystroglycanopathy syndrome with severe epilepsy. Ann. Neurol. 2012, 72, 550-558. [CrossRef] [PubMed]
9. Jansen, E.J.; Timal, S.; Ryan, M.; Ashikov, A.; van Scherpenzeel, M.; Graham, L.A.; Mandel, H.; Hoischen, A.; Iancu, T.C.; Raymond, K. et al. ATP6AP1 deficiency causes an immunodeficiency with hepatopathy, cognitive impairment and abnormal protein glycosylation. Nat. Commun. 2016, 7, 11600. [CrossRef] [PubMed]
10. Jansen, J.C.; Cirak, S.; van Scherpenzeel, M.; Timal, S.; Reunert, J.; Rust, S.; Perez, B.; Vicogne, D.; Krawitz, P.; Wada, Y. et al. CCDC115 deficiency causes a disorder of Golgi homeostasis with abnormal protein glycosylation. Am. J. Hum. Genet. 2016, 98, 310-321. [CrossRef] [PubMed]
11. Jansen, J.C.; Timal, S.; van Scherpenzeel, M.; Michelakakis, H.; Vicogne, D.; Ashikov, A.; Moraitou, M.; Hoischen, A.; Huijben, K.; Steenbergen, G. et al. TMEM199 deficiency is a disorder of Golgi homeostasis characterized by elevated aminotransferases, alkaline phosphatase, and cholesterol and abnormal glycosylation. Am. J. Hum. Genet. 2016, 98, 322-330. [CrossRef] [PubMed]
12. Scott, K.; Gadomski, T.; Kozicz, T.; Morava, E. Congenital disorders of glycosylation: New defects and still counting. J. Inherit. Metab. Dis. 2014, 37, 609-617. [CrossRef] [PubMed]
13. Peanne, R.; de Lonlay, P.; Foulquier, F.; Kornak, U.; Lefeber, D.J.; Morava, E.; Perez, B.; Seta, N.; Thiel, C.; Van Schaftingen, E. et al. Congenital disorders of glycosylation (CDG): Quo vadis? Eur. J. Med. Genet. 2017. [CrossRef] [PubMed]
14. De Diego, V.; Martinez-Monseny, A.F.; Muchart, J.; Cuadras, D.; Montero, R.; Artuch, R.; Perez-Cerda, C.; Perez, B.; Perez-Duenas, B.; Poretti, A. et al. Longitudinal volumetric and 2D assessment of cerebellar atrophy in a large cohort of children with phosphomannomutase deficiency (PMM2-CDG). J. Inherit. Metab. Dis. 2017. [CrossRef]
15. Schiff, M.; Roda, C.; Monin, M.L.; Arion, A.; Barth, M.; Bednarek, N.; Bidet, M.; Bloch, C.; Boddaert, N.; Borgel, D. et al. Clinical, laboratory and molecular findings and long-term follow-up data in 96 french patients with PMM2-CDG (phosphomannomutase 2-congenital disorder of glycosylation) and review of the literature. J. Med. Genet. 2017. [CrossRef] [PubMed]
16. Panneerselvam, K.; Freeze, H.H. Mannose corrects altered N-glycosylation in carbohydrate-deficient glycoprotein syndrome fibroblasts. J. Clin. Investig. 1996, 97, 1478-1487. [CrossRef] [PubMed]
17. Kjaergaard, S.; Kristiansson, B.; Stibler, H.; Freeze, H.H.; Schwartz, M.; Martinsson, T.; Skovby, F. Failure of short-term mannose therapy of patients with carbohydrate-deficient glycoprotein syndrome type 1A. Acta Paediatr. 1998, 87, 884-888. [CrossRef] [PubMed]
18. Mayatepek, E.; Kohlmuller, D. Mannose supplementation in carbohydrate-deficient glycoprotein syndrome type I and phosphomannomutase deficiency. Eur. J. Pediatr. 1998, 157, 605-606. [CrossRef] [PubMed]
19. Harms, H.K.; Zimmer, K.P.; Kurnik, K.; Bertele-Harms, R.M.; Weidinger, S.; Reiter, K. Oral mannose therapy persistently corrects the severe clinical symptoms and biochemical abnormalities of phosphomannose isomerase deficiency. Acta Paediatr. 2002, 91, 1065-1072. [CrossRef] [PubMed]
20. De Lonlay, P.; Seta, N. The clinical spectrum of phosphomannose isomerase deficiency, with an evaluation of mannose treatment for CDG-Ib. Biochim. Biophys. Acta 2009, 1792, 841-843. [CrossRef] [PubMed]
21. Mention, K.; Lacaille, F.; Valayannopoulos, V.; Romano, S.; Kuster, A.; Cretz, M.; Zaidan, H.; Galmiche, L.; Jaubert, F.; de Keyzer, Y. et al. Development of liver disease despite mannose treatment in two patients with CDG-Ib. Mol. Genet. Metab. 2008, 93, 40-43. [CrossRef] [PubMed]
22. Schroeder, A.S.; Kappler, M.; Bonfert, M.; Borggraefe, I.; Schoen, C.; Reiter, K. Seizures and stupor during intravenous mannose therapy in a patient with CDG syndrome type 1b (MPI-CDG). J. Inherit. Metab. Dis. 2010, 33 (Suppl. S3), S497-S502. [CrossRef] [PubMed]
23. Janssen, M.C.; de Kleine, R.H.; van den Berg, A.P.; Heijdra, Y.; van Scherpenzeel, M.; Lefeber, D.J.; Morava, E. Successful liver transplantation and long-term follow-up in a patient with MPI-CDG. Pediatrics 2014, 134, e279-e283. [CrossRef] [PubMed]
24. Tegtmeyer, L.C.; Rust, S.; van Scherpenzeel, M.; Ng, B.G.; Losfeld, M.E.; Timal, S.; Raymond, K.; He, P.; Ichikawa, M.; Veltman, J. et al. Multiple phenotypes in phosphoglucomutase 1 deficiency. N. Engl. J. Med. 2014, 370, 533-542. [CrossRef] [PubMed]
25. Morava, E. Galactose supplementation in phosphoglucomutase-1 deficiency; review and outlook for a novel treatable CDG. Mol. Genet. Metab. 2014, 112, 275-279. [CrossRef] [PubMed]
26. Wong, S.Y.; Gadomski, T.; van Scherpenzeel, M.; Honzik, T.; Hansikova, H.; Holmefjord, K.S.B.; Mork, M.; Bowling, F.; Sykut-Cegielska, J.; Koch, D. et al. Oral D-galactose supplementation in PGM1-CDG. Genet. Med. 2017. [CrossRef] [PubMed]
27. Kodera, H.; Nakamura, K.; Osaka, H.; Maegaki, Y.; Haginoya, K.; Mizumoto, S.; Kato, M.; Okamoto, N.; Iai, M.; Kondo, Y. et al. De novo mutations in SLC35A2 encoding a UDP-galactose transporter cause early-onset epileptic encephalopathy. Hum. Mutat. 2013, 34, 1708-1714. [CrossRef] [PubMed]
28. Dorre, K.; Olczak, M.; Wada, Y.; Sosicka, P.; Gruneberg, M.; Reunert, J.; Kurlemann, G.; Fiedler, B.; Biskup, S.; Hortnagel, K. et al. A new case of UDP-galactose transporter deficiency (SLC35A2-CDG): Molecular basis, clinical phenotype, and therapeutic approach. J. Inherit. Metab. Dis. 2015, 38, 931-940. [CrossRef] [PubMed]
29. Park, J.H.; Hogrebe, M.; Fobker, M.; Brackmann, R.; Fiedler, B.; Reunert, J.; Rust, S.; Tsiakas, K.; Santer, R.; Gruneberg, M. et al. SLC39A8 deficiency: Biochemical correction and major clinical improvement by manganese therapy. Genet. Med. 2017. [CrossRef] [PubMed]
30. Park, J.H.; Hogrebe, M.; Gruneberg, M.; DuChesne, I.; von der Heiden, A.L.; Reunert, J.; Schlingmann, K.P.; Boycott, K.M.; Beaulieu, C.L.; Mhanni, A.A. et al. SLC39A8 deficiency: A disorder of manganese transport and glycosylation. Am. J. Hum. Genet. 2015, 97, 894-903. [CrossRef] [PubMed]
31. Riley, L.G.; Cowley, M.J.; Gayevskiy, V.; Roscioli, T.; Thorburn, D.R.; Prelog, K.; Bahlo, M.; Sue, C.M.; Balasubramaniam, S.; Christodoulou, J. A SLC39A8 variant causes manganese deficiency, and glycosylation and mitochondrial disorders. J. Inherit. Metab. Dis. 2017, 40, 261-269. [CrossRef] [PubMed]
32. Foulquier, F.; Amyere, M.; Jaeken, J.; Zeevaert, R.; Schollen, E.; Race, V.; Bammens, R.; Morelle, W.; Rosnoblet, C.; Legrand, D. et al. TMEM165 deficiency causes a congenital disorder of glycosylation. Am. J. Hum. Genet. 2012, 91, 15-26. [CrossRef] [PubMed]
33. Zeevaert, R.; de Zegher, F.; Sturiale, L.; Garozzo, D.; Smet, M.; Moens, M.; Matthijs, G.; Jaeken, J. Bone dysplasia as a key feature in three patients with a novel congenital disorder of glycosylation (CDG) type II due to a deep intronic splice mutation in tmem165. JIMD Rep. 2013, 8, 145-152. [PubMed]
34. Theodore, M.; Morava, E. Congenital disorders of glycosylation: Sweet news. Curr. Opin. Pediatr. 2011, 23, 581-587. [CrossRef] [PubMed]
35. Rymen, D.; Peanne, R.; Millon, M.B.; Race, V.; Sturiale, L.; Garozzo, D.; Mills, P.; Clayton, P.; Asteggiano, C.G.; Quelhas, D. et al. MAN1B1 deficiency: An unexpected CDG-II. PLoS Genet. 2013, 9, e1003989. [CrossRef] [PubMed]
36. Los, E.L.; Lukovac, S.; Werner, A.; Dijkstra, T.; Verkade, H.J.; Rings, E.H. Nutrition for children with cholestatic liver disease. Nestle Nutr. Workshop Ser. Pediatr. Program. 2007, 59, 147-157. [PubMed]
37. Neal, E.G.; Chaffe, H.; Schwartz, R.H.; Lawson, M.S.; Edwards, N.; Fitzsimmons, G.; Whitney, A.; Cross, J.H. The ketogenic diet for the treatment of childhood epilepsy: A randomised controlled trial. Lancet Neurol. 2008, 7, 500-506. [CrossRef]
38. Freeze, H.H. Towards a therapy for phosphomannomutase 2 deficiency, the defect in CDG-IA patients. Biochim. Biophys. Acta 2009, 1792, 835-840. [CrossRef] [PubMed]
39. Schrapers, E.; Tegtmeyer, L.C.; Simic-Schleicher, G.; Debus, V.; Reunert, J.; Balbach, S.; Klingel, K.; Du Chesne, I.; Seelhofer, A.; Fobker, M. et al. News on clinical details and treatment in PGM1-CDG. JIMD Rep. 2016, 26, 77-84. [PubMed]
40. Marquardt, T.; Luhn, K.; Srikrishna, G.; Freeze, H.H.; Harms, E.; Vestweber, D. Correction of leukocyte adhesion deficiency type II with oral fucose. Blood 1999, 94, 3976-3985. [PubMed]
41. Koch, J.; Mayr, J.A.; Alhaddad, B.; Rauscher, C.; Bierau, J.; Kovacs-Nagy, R.; Coene, K.L.; Bader, I.; Holzhacker, M.; Prokisch, H. et al. CAD mutations and uridine-responsive epileptic encephalopathy. Brain 2017, 140, 279-286. [CrossRef] [PubMed]